Advocating on issues related to pharmaceuticals and pharmaceutical manufacturing.
Registered Lobbyists (2)
HEATHER TURNBULL ●NEWWILLIAM RUBIN ●NEW
IDs
Filing UUID:9f60e65a-8de5-4fc5-88e7-0495068ed95d
Registrant ID:401106132
Client ID:67435
2025-07-02
REPUBLIC CONSULTING, LLC
GRAVITY DIAGNOSTICS
$20,000
$0
Filing Details
Type: ld2 • Year: 2025 Q2
Specific Issues
Monitor policy and budget related to pharmacogenetic testing.
Government Entities
Defense, Dept of (DOD), SENATE
Registered Lobbyists (1)
JODY HOFFMAN
IDs
Filing UUID:552e1436-0d05-4a9f-99f3-6507da4751fd
Registrant ID:401016871
Client ID:54981
2025-07-02
REPUBLIC CONSULTING, LLC
GRAVITY DIAGNOSTICS
$20,000
$0
Filing Details
Type: ld2 • Year: 2025 Q2
Specific Issues
Monitor policy and budget related to pharmacogenetic testing.
Government Entities
Defense, Dept of (DOD), SENATE
Registered Lobbyists (1)
JODY HOFFMAN
IDs
Filing UUID:228319ab-3798-4a03-9e5b-c0fe856950f6
Registrant ID:401016871
Client ID:54981
2025-07-01
CRANE STRATEGIES
REGENERON PHARMACEUTICALS, INC.
$50,000
$0
Filing Details
Type: ld2 • Year: 2025 Q2
Specific Issues
Biodefense funding
Government Entities
Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE
Registered Lobbyists (1)
STEVEN CRANE — Staff assistant, Senator Barbara Mikulski
IDs
Filing UUID:c38ff6de-9193-4b2f-a63d-0a5cc8471a4a
Registrant ID:400927689
Client ID:196249
2025-07-01
TAUZIN STRATEGIC NETWORKS
RAZORMETRICS
$37,500
$0
Filing Details
Type: ld2 • Year: 2025 Q2
Specific Issues
Lowering Medicare & Medicaid pharmaceutical spend with advanced cost containment systems; Lowering Medicare & Medicaid pharmaceutical spend with advanced cost containment systems
Government Entities
Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Registered Lobbyists (1)
W.J. TAUZIN
IDs
Filing UUID:cdf566d8-c965-4ecd-a053-7fa4564c994b
Registrant ID:400786367
Client ID:64818
2025-07-01
DA VINCI GROUP
BOESEN & SNOW, LLC
$10,000
$0
Filing Details
Type: ld2 • Year: 2025 Q2
Specific Issues
Health Care Issues and pharmaceutical-related issues, generally; No Specific legislation during this period.
Government Entities
HOUSE OF REPRESENTATIVES, SENATE
Registered Lobbyists (1)
MARK SMITH
IDs
Filing UUID:e996d85d-f639-4db3-87a9-5dc9193840f1
Registrant ID:11548
Client ID:56318
2025-07-01
ELITE STRATEGIC SERVICES
CONSERVATIVES FOR PROPERTY RIGHTS
$15,000
$0
Filing Details
Type: ld2 • Year: 2025 Q2
Specific Issues
S. 708/H.R. 1574 (RESTORE Patent Rights Act) S. 1553/H.R. 3160 (Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act) S. 1546/H.R. 3152 (Patent Eligibility Restoration Act (PERA)) S. 1367/H.R. 2794 (NO FAKES Act) S. 1041 (Affordable Prescriptions for Patients Act) S. 1097 (Interagency Patent Coordination and Improvement Act) Comment on the World Intellectual Property Organization Treaty on Intellectual Property, Genetic Resources and Associated Traditional Knowledge (Docket No. PTO-C-2024-0048) Advancing Americas Interest Act to disadvantageously change U.S. innovator firms access to and treatment before the U.S. International Trade Commission when seeking Section 337 remedies blocking importation of U.S. patent-infringing goods Candidates and nominations for Patent & Trademark Office leadership positions and Patent Public Advisory Committee America First Trade Policy section (3)(e) China intellectual property policies Abuse of section 1498 as drug price controls to expropriate patent rights Abuse of the Inter Partes Review (IPR) process by the Patent Trial & Appeal Boards allowing cases to proceed per the egregious application of the repudiated compelling merits standard for PTAB institution; S. 832/H.R. 1492 (Ensuring Pathways to Innovative Cures (EPIC) Act) Pharmacy benefits management reform Inflation Reduction Act drug price negotiation timing H.R. 1 (One Big Beautiful Bill Act) provisions related to proposed government drug price controls known as most favored nation being added to the Medicaid program H.R. 1 (One Big Beautiful Bill Act) provisions related to Health Savings Account (HSA) reforms Centers for Medicare & Medicaid Services (CMS) Request for Comments on Medicare Drug Price Negotiation Program Draft Guidance, FR Doc. 2025-08607; H.R. 384 (One Agency Act) S. 1040 (Drug Competition Enhancement Act) S. 1096 (Preserve Access to Affordable Generics and Biosimilars Act); S. 587/H.R. 1301 (Death Tax Repeal Act) Reauthorization and making permanent key Tax Cuts and Jobs Act (TCJA) tax policies, i.e., corporate tax rates, progrowth tax incentive provisions H.R. 2230 (Independent Programmers Tax Incentive Act); Executive Order 14192, Unleashing Prosperity Through Deregulation H. Res. 294 provisions related to proxy voting; Special 301 Report - bolstering U.S. advocacy abroad for respecting intellectual property rights U.S. Trade Representative Request for Comments Regarding Foreign Nations Freeloading on American-Financed Innovation (Docket No. USTR-2025-0011); H. J. Res. 88, revoking pursuant to the Congressional Review Act California waivers from the Clean Air Act Reform of the definition of the Waters of the United States (WOTUS) under the Clean Water Act
Government Entities
Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, Centers For Medicare and Medicaid Services (CMS), U.S. Trade Representative (USTR), Army, Dept of (Corps of Engineers), Environmental Protection Agency (EPA), Small Business Administration (SBA)
Registered Lobbyists (1)
JAMES EDWARDS — LD, Rep. Ed Bryant; LA/Press Secretary, Rep. John Duncan; Special Assistant, Senate Judiciary Committee
IDs
Filing UUID:4fff56ad-83fc-4791-97dd-562ed3eee966
Registrant ID:401108852
Client ID:61568
2025-07-01
BALLARD PARTNERS
NOVO NORDISK INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Guidance regarding pharmaceutical regulations.
Registered Lobbyists (3)
BRIAN BALLARD ●NEWMONICA RODRIGUEZ ●NEWSYLVESTER LUKIS ●NEW
IDs
Filing UUID:6890bfed-e777-43de-84d8-e52df1efc6cb
Registrant ID:401104288
Client ID:67420
2025-07-01
E3 STRATEGIC CONSULTING GROUP
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
$50,000
$0
Filing Details
Type: ld2 • Year: 2025 Q2
Specific Issues
Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing, supply chain issues, pharmacy benefit managers transparency issues, Intellectual property, trade, and employment issues, generally; S. 1040, Drug Competition Enhancement Act; H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program
Government Entities
HOUSE OF REPRESENTATIVES, SENATE
Registered Lobbyists (1)
PATRICK FOLEY
IDs
Filing UUID:f0f4bac9-f255-48cb-a50f-0a9666ec0ff5
Registrant ID:401104104
Client ID:200765
2025-06-30
STANTON PARK GROUP
KYOWA KIRIN
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
FDA modernization policy issues; General issues related to rare disease and clinical trials; General issues related to diagnostics for patients with rare diseases; Issues related to drug pricing; Issues related to reform of pharmacy benefit managers; Issues related to trade; Issues related to Newborn Screening and Genetic Testing;; FDA modernization policy issues; General issues related to rare disease and clinical trials; General issues related to diagnostics for patients with rare diseases; Issues related to drug pricing; Issues related to reform of pharmacy benefit managers; Issues related to trade; Issues related to Newborn Screening and Genetic Testing;
Registered Lobbyists (5)
AISLING MCDONOUGH ●NEW— Chief of Staff, Rep. Anna Eshoo; Senior Health Advisor, Rep. Anna Eshoo; Policy Coordinator, Energy & Commerce Committee; Legislative Assistant, Sen. Brian SchatzBRYAN WELLS ●NEW— Policy Advisor, Sen. Pat RobertsJAMES DERDERIAN ●NEW— Chief of Staff, House Commerce Committee; Legislative Advisor to Rep. Tom BlileyJOSEPH RACHINSKY ●NEWVALERIE HENRY ●NEW— Legislative Director, Rep. Greg Walden; Legislative Assistant to Sen. John Warner and Sen. Mike Crapo
IDs
Filing UUID:d4b3502a-85a6-42a8-857b-4e03d8177c00
Registrant ID:83717
Client ID:67358
2025-06-27
PARATEK PHARMACEUTICALS
PARATEK PHARMACEUTICALS
$0
$20,000
Filing Details
Type: ld2 • Year: 2025 Q2
Specific Issues
FY 26 DOD Appropriations FY 26 HHS Appropriations Biodefense Funding
Government Entities
Defense, Dept of (DOD), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE
Registered Lobbyists (1)
BENJAMIN NOVAK
IDs
Filing UUID:57c39237-8724-496e-9b83-69dbbf8c8e88
Registrant ID:401109327
Client ID:64825
2025-06-25
CONTINENTAL STRATEGY, LLC
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA)
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
policy issues related to drug pricing, payment policy, and regulatory oversight.; policy issues related to drug pricing, payment policy, and regulatory oversight.
Registered Lobbyists (2)
CHRISTOPHER MILES ●NEW— Deputy Chief of Staff to Carlos CurbeloTIMOTHY COSTA ●NEW
IDs
Filing UUID:bf0e45d0-9725-490a-bc47-50244ba24450
Registrant ID:401106285
Client ID:67288
2025-06-24
CAROL G HOLLADAY & ASSOCIATES
PHARMADVA
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Medical Device tariff impacts, expanding access for new medical technology within the VA, S. 1874 Nursing Workforce Reauthorization Act, section 3 - strengthening capacity for Nurse Education & Practices, expand the types of equipment and telehealth technologies the bill supports.; Medical Device tariff impacts, expanding access for new medical technology within the VA, S. 1874 Nursing Workforce Reauthorization Act, section 3 - strengthening capacity for Nurse Education & Practices, expand the types of equipment and telehealth technologies the bill supports.
Registered Lobbyists (1)
CAROL GRAVES HOLLADAY ●NEW
IDs
Filing UUID:7683f8e8-315c-4812-9184-130e512418f5
Registrant ID:401106369
Client ID:67276
2025-06-23
BALLARD PARTNERS
RIO BIOPHARMACEUTICALS, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Assisting with applications before the Food & Drug Administration for generic pharmaceutical approvals.
Registered Lobbyists (4)
ALISON ANWAY ●NEW— LA to Senator Pat Roberts 2006-2010BRIAN BALLARD ●NEWJOSE DIAZ ●NEWSYLVESTER LUKIS ●NEW
IDs
Filing UUID:5f14b94d-9735-45dd-b4eb-0e6d8e04399e
Registrant ID:401104288
Client ID:67244
2025-06-20
DGA GROUP GOVERNMENT RELATIONS LLC
FEDERATION OF PHARMACEUTICAL WHOLESALERS, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Trade policy support in regard to non-tariff trade barriers
Registered Lobbyists (1)
JUSTIN MCCARTHY ●NEW— Assistant U.S. Trade Representative, 2005-2007; Special Assistant to the President; 2007-2008
IDs
Filing UUID:395c8f26-4e9b-4a0b-b43b-2aa265e366fd
Registrant ID:401106546
Client ID:67227
2025-06-17
BRIGHTSPRING HEALTH SERVICES
BRIGHTSPRING HEALTH SERVICES
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Pharmacy and provider issues - various; Pharmacy and provider issues - various; Pharmacy and provider issues - various
Registered Lobbyists (1)
ESME GREWAL ●NEW
IDs
Filing UUID:3075c0aa-7201-437e-8c9d-b546f1d936e1
Registrant ID:401109655
Client ID:67178
2025-06-16
DGA GROUP GOVERNMENT RELATIONS LLC
VIIV HEALTHCARE
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Defense of U.S. pharmaceutical intellectual property rights and innovation incentives. Foreign trade and intellectual property.
Registered Lobbyists (2)
ANDRES GARCIA ●NEWJUSTIN MCCARTHY ●NEW— Assistant U.S. Trade Representative, 2005-2007; Special Assistant to the President, 2007-2008.
IDs
Filing UUID:16b9d594-ad23-40f1-a474-1f419160d811
Registrant ID:401106546
Client ID:66695
2025-06-13
RUBIN, TURNBULL & ASSOCIATES
USANTIBIOTICS
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Advocate on issues related to pharmaceuticals and drug regulation.
Registered Lobbyists (2)
HEATHER TURNBULL ●NEWWILLIAM RUBIN ●NEW
IDs
Filing UUID:3639d6ec-4c8f-442c-a2ac-3d3d77ccd6b7
Registrant ID:401106132
Client ID:67099
2025-06-13
RUBIN, TURNBULL & ASSOCIATES
USANTIBIOTICS
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Advocate on issues related to pharmaceuticals and drug regulation.
Registered Lobbyists (2)
HEATHER TURNBULL ●NEWWILLIAM RUBIN ●NEW
IDs
Filing UUID:832cba91-003a-459c-97e3-33e8415df65b
Registrant ID:401106132
Client ID:67099
2025-06-13
BALLARD PARTNERS
PUBLIX SUPER MARKETS, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Labor and hiring practice issues; compliance with environmental regulations; healthcare reforms impacting pharmacies.; Labor and hiring practice issues; compliance with environmental regulations; healthcare reforms impacting pharmacies.
Registered Lobbyists (3)
ALISON ANWAY ●NEW— LA to Senator Pat Roberts 2006-2010ANA CRUZ ●NEW— Regional Director to U.S. Senator Bill Nelson (2001-2002)BRIAN BALLARD ●NEW
IDs
Filing UUID:6eb91fe3-7e16-4588-860f-dd73947bce2f
Registrant ID:401104288
Client ID:67114
2025-06-12
AGIOS PHARMACEUTICALS
AGIOS PHARMACEUTICALS
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Pharmacy, Medicare/Medicaid, Health Issues; Pharmacy, Medicare/Medicaid, Health Issues; Pharmacy, Medicare/Medicaid, Health Issues
Registered Lobbyists (1)
AARON KRUPP ●NEW
IDs
Filing UUID:38ad3da1-dd2d-46f1-87bf-da64c5a66ea4
Registrant ID:401109657
Client ID:67079
2025-06-10
LEAVITT PARTNERS, LLC
ORCHARD THERAPEUTICS NORTH AMERICA
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Newborn screening and pharmaceuticals.
Registered Lobbyists (2)
CONNOR SHEEHEY ●NEW— Senate Finance: Senior Health Policy Advisor-Chair; Senior Health Policy Advisor-RM; Health Policy Advisor-RM; Deputy Legislative Director-Senate; Legislative Assistant-Senate; Deputy Legislative Assistant-Senate; Legislative Fellow-SenateMELISSA PFAFF ●NEW— Senate HELP: Senior Health Policy Advisor-Ranking Member (RM); Senior Policy Advisor-Chair; Health Policy Advisor-Chair; Prof Staff Member-Chair; Prof Staff Member-RM; Prof Staff Member RM-Senate Budget; Leg Corres-Senate; Staff Assistant-Senate
IDs
Filing UUID:28e4ecbd-ec26-41a3-8868-f119f541c972
Registrant ID:401103367
Client ID:67047
2025-06-10
KYOWA KIRIN, INC
KYOWA KIRIN, INC
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
FDA modernization policy issues General issues related to rare disease and clinical trials General issues related to diagnostics for patients with rare diseases Issues related to drug pricing Issues related to reform of pharmacy benefit managers Issues related to trade Issues related to Newborn Screening and Genetic Testing
Registered Lobbyists (1)
EDWARD BUCKLEY ●NEW
IDs
Filing UUID:8729b8cb-6077-455e-ab4f-70d57167fe18
Registrant ID:401109649
Client ID:67055
2025-05-30
MILLER STRATEGIES, LLC
GILEAD SCIENCES, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Issues related to pharmaceuticals and drug development.; Issues related to pharmaceuticals and drug development.; Issues related to pharmaceuticals and drug development.
Registered Lobbyists (3)
ASHLEY GUNN ●NEW— Special Asst to the President, Senior Director, White House Office of Cabinet Affairs.JAMES MIN ●NEW— Chief of Staff, Rep. Vince Fong; Chief of Staff, Office of the 20th District of California; Chief of Staff, Deputy Chief of Staff, and Counsel, Speaker Kevin McCarthy; Chief of Staff, Rep. Bill ThomasJEFFREY MILLER ●NEW